This federal contract IDV award by the National Cancer Institute (NCI), a civilian agency, provides for research and development services to support preclinical pharmacokinetic and pharmacology evaluations of agents being developed for cancer patients. The prime contractor is the University of Pittsburgh - Of The Commonwealth System of Higher Education, a major public research university with extensive experience conducting federal research contracts and grants across biomedical sciences. The...
This indefinite delivery contract was awarded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH) under the Department of Health and Human Services (HHS). The contract, valued at up to $74,995,000, is a multiple award with Advanced Bioscience Laboratories, Inc. (ABL) as the prime contractor. The contract supports the PREVENT Cancer Preclinical Drug Development Program, with the objective of cGMP production of vaccines and biologicals for cancer prevention. Key...
The Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Cancer Institute (NCI) awarded a multiple-award indefinite delivery/indefinite quantity (IDIQ) contract to Weill Medical College of Cornell University to provide preclinical research services for the PREVENT Cancer Preclinical Drug Development Program. Under this $149,995,000 IDIQ, the contractor performs efficacy testing, biomarker evaluation, and analytical assay development to advance cancer...
The National Cancer Institute awarded an indefinite delivery/indefinite quantity multiple award contract to provide operational, administrative, regulatory, information technology, and logistical support services to support participation in multi-institutional cancer trials. Valued at up to $548 million over 10 years, the contract includes six task areas: project kick-off and transition activities, CTSU core support services and systems, awareness and training, site study set-up, protocol and...
The National Cancer Institute, part of the National Institutes of Health within the Department of Health and Human Services, awarded a single award Indefinite Delivery Contract to Alchem Laboratories Corporation. The contract has a potential value of $7,777,665 and a period of performance from September 2017 to September 2022. Under the contract, Alchem Laboratories Corporation provides non-good manufacturing practices synthesis of small molecules to support the National Cancer Institute's...
The National Cancer Institute (NCI) awarded a $74,995,000 multiple-award indefinite delivery/indefinite quantity (IDIQ) contract called the PREVENT Preclinical Drug Development Program to support preclinical pharmacology, toxicology, and product development services for cancer therapy candidates. The prime contractor, IIT Research Institute (IITRI), is a non-profit division of the Illinois Institute of Technology that specializes in these preclinical services for federal agencies. Under this...
The National Cancer Institute (NCI) awarded a multiple-award Indefinite Delivery Contract (IDC) with a $149,995,000 ceiling value to The Institute For Cancer Research, a non-profit organization and subsidiary of Temple University, to provide preclinical efficacy and biomarker analysis services in support of the PREVENT Cancer Preclinical Drug Development Program. This 5-year IDC contract includes three technical pools: Preclinical Efficacy and Biomarkers, Preclinical Services for Product...
Alchem Laboratories Corporation was awarded a single award indefinite delivery contract by the National Cancer Institute, part of the National Institutes of Health within the Department of Health and Human Services. The contract has a potential value of $12,069,385 and a period of performance through April 10, 2028. The contract aims to procure analysis and synthesis of Good Manufacturing Practice and non-GMP bulk drugs and pharmaceutical formulations to support the National Cancer Institute's...
The National Center for Advancing Translational Sciences (NCATS), a civilian agency, has awarded an indefinite delivery contract (IDC) worth up to $48,622,546 to Charles River Laboratories, Inc. to provide safety evaluation and toxicology studies and related services to support drug development. The contract has a period of performance from August 2024 to August 2030. Under this IDC, Charles River will perform in vitro and in vivo exploratory and Investigational New Drug (IND)-directed...
The University of Texas MD Anderson Cancer Center was awarded an indefinite delivery, indefinite quantity (IDIQ) contract from the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), to support the PREVENT Preclinical Drug Development Program. This multiple award IDIQ has a $74,995,000 ceiling and a 5-year base period with a 5-year option. It covers three pools of services: preclinical efficacy and biomarker evaluation, preclinical GMP product development and...